Phase II Evaluation of Dalantercept, a Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK1) Receptor Fusion Protein, for the Treatment of Recurrent or Persistent Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study 0229N

OBJECTIVE: This two-stage phase II study assessed activity of single agent dalantercept in patients with recurrent/persistent endometrial carcinoma (EMC). METHODS: Eligible patients had persistent/recurrent EMC after 1–2 prior cytotoxic regimens, measurable disease (RECIST 1.1), and GOG performance...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Gynecol Oncol
Главные авторы: Makker, Vicky, Filiaci, Virginia L., Chen, Lee-may, Darus, Christopher J., Kendrick, James E., Sutton, Gregory, Moxley, Katherine, Aghajanian, Carol
Формат: Artigo
Язык:Inglês
Опубликовано: 2015
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4615687/
https://ncbi.nlm.nih.gov/pubmed/25888978
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2015.04.006
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы